Rubius Therapeutics Inc (NASDAQ:RUBY) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 7,674,000 shares, a growth of 10.3% from the May 30th total of 6,956,300 shares. Based on an average trading volume of 249,700 shares, the short-interest ratio is presently 30.7 days. Approximately 25.4% of the shares of the stock are short sold.
A number of research firms have recently issued reports on RUBY. Guggenheim reaffirmed a “hold” rating on shares of Burlington Stores in a report on Thursday, May 30th. HC Wainwright reiterated a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Finally, Zacks Investment Research upgraded shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, June 4th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Rubius Therapeutics presently has an average rating of “Buy” and a consensus target price of $31.00.
In other news, insider Christopher L. Carpenter sold 47,757 shares of Rubius Therapeutics stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $14.02, for a total transaction of $669,553.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 58.40% of the company’s stock.
Large investors have recently modified their holdings of the stock. Jennison Associates LLC increased its position in shares of Rubius Therapeutics by 0.4% in the first quarter. Jennison Associates LLC now owns 479,398 shares of the company’s stock valued at $8,677,000 after acquiring an additional 1,802 shares during the period. Metropolitan Life Insurance Co NY increased its position in shares of Rubius Therapeutics by 65.0% in the first quarter. Metropolitan Life Insurance Co NY now owns 11,867 shares of the company’s stock valued at $214,000 after acquiring an additional 4,676 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Rubius Therapeutics by 320.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock valued at $116,000 after acquiring an additional 5,481 shares during the period. MetLife Investment Advisors LLC increased its position in shares of Rubius Therapeutics by 52.2% in the first quarter. MetLife Investment Advisors LLC now owns 16,410 shares of the company’s stock valued at $297,000 after acquiring an additional 5,629 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Rubius Therapeutics in the first quarter valued at about $117,000. Institutional investors own 93.75% of the company’s stock.
Shares of NASDAQ:RUBY opened at $14.78 on Tuesday. The stock has a market cap of $1.23 billion and a PE ratio of -6.51. The stock has a fifty day simple moving average of $14.76. Rubius Therapeutics has a 52 week low of $12.70 and a 52 week high of $33.01. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64.
Rubius Therapeutics (NASDAQ:RUBY) last issued its earnings results on Wednesday, May 15th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). On average, equities research analysts predict that Rubius Therapeutics will post -1.84 EPS for the current fiscal year.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Further Reading: Dividend Aristocrat Index
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.